Loading
Nephros Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 30 May 2024.
Nephros Inc: what insiders have been doing
Nephros Inc is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). Over the twelve months to 18 October 2026, 14 filings were filed, from 6 insiders.
The filings describe grants, exercises and other transfers rather than trades on the open market. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
With 14 filings in twelve months, the company is quieter than the median of 19 filings across the 5,814 companies we follow on the same exchange. Since 2021, the database holds 9 purchases and no sales by insiders of the company.
Insider buying of Nephros Inc has been absent for the past year. Typically, a trade is published a median of 2 days after it takes place. Section 16 rules allow two business days to file each Form 4.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Anixa Biosciences Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
44
Thresholds
n/a
Buy Volume
€218,562
9 ops. · all time
Sell Volume
n/a
n/a
Since the insiders bought
- +43.6%Entry US$2.18 · Close at T+365 US$3.13
- -37.7%Entry US$2.57 · Close at T+365 US$1.60
- -84.0%Entry US$8.70 · Close at T+365 US$1.39
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 9,504 of 24,158 companies
56.9
score / 100
Value42
Quality72
FCF yld4.1%
Earn yld3.0%
EV/EBITDA30.2x
ROE16%
Gross mgn62%
Net mgn6.4%
Debt/EBITDA0.8x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$3.52
Analyst consensus
3 analysts2.00/5
US$4.75Target US$6.25(+78%)US$8.00
Income statement
RevenueUS$18.8M
Gross profitUS$11.6M62% margin
EBITDAUS$1.3M7% margin
Net incomeUS$1.2M8.4% margin
Valuation
PER (trailing)23.5x
PER (forward)16.8x
P/Book3.2x
Beta1.64
Balance sheet & cash
Market capUS$38.2M
Total debtUS$1.1M
Free Cash FlowUS$1.6M
Debt / Equity7%
Profitability & ownership
ROE16.1%
ROA7.3%
% insiders18.7%
% institutions17.8%
Last declaration on 16 September 2026
Declarations44 total
17,749 shares0Common StockSEC:0001398344-26-017116:0
2,836 shares0Common StockSEC:0001398344-26-017116:1
22,710 shares@ US$3.950.19% mcap79.7% of flowCommon StockSEC:0001398344-26-017116:2
3,355,111 shares0Common StockSEC:0001398344-26-017120:0
22,710 shares@ US$3.950.19% mcap34.1% of flowCommon StockSEC:0001398344-26-017120:1
812 shares@ US$3.600.0062% mcap1.1% of flowCommon StockSEC:0001398344-26-015086:0
2,418 shares0Common StockSEC:0000914190-26-000110:0
3,574 shares0Common StockSEC:0000914190-26-000098:0
68,861 shares@ US$1.71100.0% of flowCommon StockSEC:0000914190-26-000052:0
120,000 shares@ US$1.4451.1% of flowCommon StockSEC:0000914190-26-000053:0
3,610 shares0Common StockSEC:0000914190-26-000042:0
1,622 shares0Common StockSEC:0000914190-25-000041:0
5,391 shares0Common StockSEC:0000914190-25-000039:0
8,036 shares0Common StockSEC:0000914190-25-000040:0
22,418 shares0Common StockSEC:0001062993-25-000264:0
33,241 shares0Common StockSEC:0001062993-25-000233:0
2,000 shares@ US$2.22074.2% of flowCommon StockSEC:0001062993-24-011498:0
Canonical exit: 26 Aug 2024 (T+90)
50,000 shares@ US$2.24135.3% of flowCommon StockSEC:0001062993-24-010486:0
Canonical exit: 14 Aug 2024 (T+90)
91,463 shares0Common StockSEC:0001048462-24-000012:0
7,000 shares@ US$2.447116.1% of flowCommon stockSEC:0001048462-24-000011:0
Canonical exit: 10 Jun 2024 (T+90)
9,291 shares0Common StockSEC:0001062993-23-022642:0
9,291 shares0Common StockSEC:0001062993-23-022643:0
9,291 shares0Common StockSEC:0001062993-23-022644:0
14,294 shares0Common StockSEC:0001062993-23-022645:0
18,000 shares@ US$2.202612.6% of flowCommon StockSEC:0001062993-23-022326:0
Canonical exit: 6 Mar 2024 (T+90)
25 of 44 declarations
About Nephros Inc
Nephros, Inc. (ticker: NEPH) is listed on the Nasdaq market in the United States (United States) and operates as a specialist in water-filtration solutions for medical and commercial applications. For French-speaking investors, the company sits at the intersection of healthcare technology, regulated filtration products, and critical infrastructure rather than in traditional “pure-play” medtech. Its core value proposition is water safety: reducing contaminants and supporting sanitary requirements in sensitive environments such as hospitals, dialysis centers, and commercial facilities where water quality is operationally important. ([nephros.com](https://www.nephros.com/investors/?utm_source=openai))
Nephros was originally founded by health professionals, scientists, and engineers affiliated with Columbia University, with a historical focus on technology and products for end-stage renal disease therapy. Over time, the company evolved into a broader water-technology business. According to company disclosures, its headquarters, research, manufacturing, and distribution functions are concentrated in New Jersey, with facilities in South Orange and Whippany. This footprint gives the company tighter control over product development and delivery while keeping the organization relatively lean. ([fintel.io](https://fintel.io/doc/sec-nephros-inc-1196298-10k-2025-march-24-20171-4878?utm_source=openai))
Read moreShow less
From a business-model perspective, Nephros sells filtration products and related solutions across two main end markets: medical and commercial. In medical applications, the company serves infection-control and dialysis-related use cases, where reliability and regulatory compliance are essential. In commercial applications, the offering targets customers that require consistent water-quality management for safety, equipment protection, and operational continuity. Management also emphasizes an integrated approach combining products, service, and education, which points to a strategy aimed at building recurring relationships and customer retention rather than relying solely on one-time product sales. ([nephros.com](https://www.nephros.com/investors/?utm_source=openai))
Competitive positioning is that of a focused niche player. Nephros is not a global giant, but it differentiates itself through specialization in water filtration for critical environments, regulatory positioning, and a product set designed for high-stakes settings. Recent disclosures suggest that this strategy has been gaining traction: throughout 2025 and into early 2026, the company reported strong revenue growth, record programmatic sales, and expanding active-site counts. It also launched a new S100 in-line microfilter in 2025, which management described as extending the portfolio between microfiltration and ultrafiltration. ([nasdaq.com](https://www.nasdaq.com/press-release/nephros-announces-strong-third-quarter-financial-results-achieving-highest-level?utm_source=openai))
For investors, NEPH offers a combination of defensive end-market exposure, regulatory barriers, and growth potential tied to water-quality needs in healthcare and commercial settings. At the same time, the company’s recent commentary on tariffs and supply-chain conditions highlights exposure to input-cost pressure and execution risk. Overall, Nephros remains a small-cap Nasdaq-listed company with a specialized franchise and a recent operating momentum that may support investor interest, provided one accepts the risks typical of smaller, niche industrial-healthcare businesses. ([nasdaq.com](https://www.nasdaq.com/press-release/nephros-announces-fourth-quarter-and-record-fiscal-year-2025-financial-results-2026?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
